About Cybin Inc. (CYBN)

Cybin Inc. is a clinical-stage biopharmaceutical company, which develops psychedelic-based therapeutics. It was founded in 2019 and is publicly traded on the NYSE American and Cboe CA under the ticker symbol “CYBN.”

The company’s mission is to develop safe and effective therapeutics for patients to address a various kinds of mental health issues.

The company has developed a pipeline of nearly 50 different proprietary psychedelic molecules which are based on DMT, MDMA, Psilocybin, and other analogues. Here are some of the drug programs the company has developed:

• CYB003: A deuterated psilocybin analog, currently in Phase 1/2a clinical trials for treating major depressive and alcohol use disorders.
• CYB004: A deuterated dimethyltryptamine, in Phase 1 clinical trials for treating generalized anxiety disorders.
• CYB005: A phenethylamine derivative, in preclinical stages aimed at treating neuroinflammation.

These programs are basically designed to make better use of advanced technologies, such as Kernel Flow neuroimaging, to enhance understanding and effectiveness of psychedelic therapies.

The company is headquartered in Toronto, Canada and operates in multiple countries, including the United States, United Kingdom, and Ireland.

Cybin Inc (CYBN) Stock Performance

Cybin Inc (NYSEAMERICAN: CYBN) went public through a reverse merger in August 2021, with its shares opening at $3.90 on the first trading day. The stock quickly rallied over 60% to hit an intraday high of $6.59 the same day, but it was short lived as CBYN’s shares began downtrend over the next several months.

Since then, Cybin Inc’s stock has had a tough time maintaining its value, facing a consistent downward trend with brief moments of upward spikes. Here’s how CYBN stock has performed over the last 6 months, 1 year and 3 years:

• 6-Month Performance: The stock started at $0.4405, climbed to $0.7380, then took a sharp fall, closing at about $0.3550. That’s a 19.41% drop in six months.
• 1-Year Performance: The stock has generally trended downwards, with a slight decline of 0.84%. It started at $0.3580 but then fell down to $0.3550. The highest price over the last year was $0.7380, while the lowest was $0.2100.
• 3-Year Performance: In the last 2 years, stock has fallen by 50.82%, and If we extend that timeline to 3 years, the stock plummeted even more, falling by 80.28% from current price.

The stock reached new highs several times across different periods, but these were often followed by sharp declines, as seen in the 52-week record of reaching a high 9 times, but declining subsequently by 51.90%. Well, This overall performance suggests a bearish outlook for CYBN stock.

CYBN Price History

Here’s a table that shows the price history of Cybin Inc. to give you a better understanding on how the stock has steeply declined, year to year, since it went public.

Cybin Inc (CYBN) Financials

In the last three years, Cybin Inc hasn’t generated any revenue or profits from commercial operations. Also, let’s look at some other metrics to understand the company’s position in the market.

1. Earnings Per Share (EPS)

In the past three years, Cybin Inc. has seen variations in its earnings per share (EPS), which tells you about company’s profitability per stock. In 2021, the company reported an EPS of -0.40, which meant that the company was not profitable. But, The EPS improved a little bit, moving to -$0.26 in 2022, but fell again to -$0.30 in 2023, reflecting continued losses.

2. Free Cash Flow (FCF)

Free cash flow has been negative, widening from -$19,258k in 2021 to -$59,752k in 2023. This increasing cash burn suggests that the company is spending more cash than it is generating. But, it’s pretty standard for companies facing financial hurdles or those reinvesting earnings back into expansion and development.

3. Market capitalization

One good thing is that company’s market cap has shown immense growth from $76.84M in 2021 to $266.92M in 2023. This increase tells that investors may be seeing potential in Cybin despite the financial problems the company might be facing today.

4. P/B Ratio

The price-to-book (P/B) ratio, which tells if a stock is undervalued or overvalued, decreased from 4.56 in 2022 to 3.05 in 2023, after being at 1.81 in 2021. These numbers suggest that the market values the company more than its net assets, but this decreasing trend might point towards a narrowing gap between market perception and asset value.

Other than this, Cybin does not pay dividends, which is quite typical for early-stage biotech companies as they reinvest their cash into research and development for drugs. Also, Cybin’s current ratio of 5.76 in 2023 is a very healthy figure, meaning its current assets can cover current liabilities nearly six times over.

Here’s what other financial metric looks like:

Cybin (CYBN) Stock Forecast & Price Prediction

If you look at the company’s stock performance in the last three years, the stock has been fluctuating between $0.5 and $1.2. It has underperformed, and with no revenue, this clearly indicates that the company is not profitable. However, with some success in drug development programs, we could see a major upside in CYBN.

If we look at the short-term forecast, the stock could rise to $1.63 in 2024, and $1.98 in 2025. And, In the long-term forecast, we could see the price reach around $3 in 2028, and $4 by 2030.

CYBN Stock Forecast & Price Prediction 2024

For 2024, analysts forecast Cybin’s average stock price to reach around $1.44, with a potential range of $1.26 to $1.63. This means that the stock could see a 198% increase from the current price. One of the major factos that could do this if we see positive results from Cybin’s ongoing Phase 2 clinical trials on drug programs – CYB003 and CYB004 – which are aimed to treat major depressive disorder and alcohol use disorder.

CYBN Stock Forecast & Price Prediction 2025

Similarly, For 2025, the average price target is $1.98, which is a 37.5% upside from 2024 predicted price, with max price and min price between $1.74 and $2.24. This positive trajectory can be expected if Cybin starts Phase 3 studies and moves closer to making regulatory submissions.

CYBN Stock Forecast & Price Prediction 2026 – 2030

Over this period, analysts project Cybin’s stock price to steadily rise, with the average forecast reaching $4.25 by 2030 (range: $3.78 – $4.70). This long-term bullish forecast is based on expectations that Cybin will achieve milestones like completing Phase 3 trials, seeking regulatory approvals, and possibly launching its first commercial psychedelic therapeutic product by late 2024.

CYBN Stock Forecast & Price Prediction 2040 and 2050

Well, the projections get more speculative If you take a look at long term forecast. But, If Cybin remains successful till late 2030s, then we can see major upside in this company’s stock. By 2040, the forecast average price is $8.54 (range: $7.64 – $9.43). And by 2050, the average projection climbs to $17.05 (range: $15.34 – $18.73).

Read More : SoundHound Inc. (SOUN) Stock Forecast & Price Prediction

Is CYBN Stock Buy, Sell or Hold?

Cybin Inc. is receiving quite optimistic evaluations from several notable financial analysts and platforms, suggesting substantial growth potential for its stock.

StockAnalysis

StockAnalysis.com gives Cybin a “Strong Buy” rating, indicating a potential upside. Their consensus price target for the stock is around $4.00, which would represent an impressive potential increase of 1,042.86% from its current price levels. Also, Key voices like Patrick Trucchio from HC Wainwright & Co. have maintained a “Strong Buy” with a price target ranging from $5 to $10, hinting at some serious confidence in the stock’s future.

Benzinga’s

Benzinga has a positive view as well, rating Cybin as a solid “Buy.” Their price targets for the stock range from $3.00 to $5.00, with a consensus target of about $3.33.

MarketBeat

MarketBeat also agrees on a “Buy” consensus for Cybin, but with a more bullish stance. They have set an optimistic price target of $7.50, which indicates a potential leap of 2,042.86% from the current price.

TipRanks

At TipRanks, Cybin Inc. is unanimously rated as a “Strong Buy” by all three analysts tracking the stock. They have set an average price target of C$6.14, which indicates a potential surge of over 4400% from its current price.

FAQs

What is CYBN forecast for 2025?

For 2025, analysts forecast Cybin’s (CYBN) stock price to average around $1.98, suggesting a 37.5% potential upside from current levels. The projected range for 2025 is $1.74 to $2.24.

What will Cybin stock be worth in 5 years?

According to analyst forecasts, Cybin’s average stock price target for 2028 is $3.18, with a range of $2.83 to $3.54.

Is Cybin a good stock to invest in?

Analysts seem optimistic, generally rating Cybin as a “Strong Buy”. According to StockAnalysis, and a “Buy” rating, according to MarketBeat, TipRanks and Bezinga.

How high can Cybin stock go?

Analyst forecasts project Cybin’s stock price could reach $17.05 on average by 2050, with a high-end estimate of $18.73. However, such long-dated price targets are highly speculative.

Who invested in Cybin?

Major investors in Cybin include a mix of institutional holders and insiders. About 6.66% of Cybin’s shares are held by insiders, indicating major skin in the game from company officials or major stakeholders. Institutions hold about 24.96% of the shares, with the float held by institutions being around 26.74%.

Top institutional holders include:

• Point72 Asset Management, L.P. holding approximately 30.06 million shares, making up 4.04% of the shares, worth $10,521,389.
• Anson Funds Management LP with 8.92 million shares or 1.20% of the shares, valued at $3,123,572.
• Alyeska Investment Group, L.p. controlling 5.68 million shares or 0.76% of the shares, worth $1,989,118.

Other notable investors are CVI Holdings, LLC, AdvisorShares Investments, LLC, and PDS Planning, Inc, among others.

Does Cybin pay dividends?

Currently, Cybin does not pay dividends. Like many biotech companies, it likely reinvests any earnings back into its research and development efforts.